Treatment for DCIS (stage 0 breast cancer) typically involves surgery to remove the abnormal cells, often followed by radiation therapy and sometimes hormone-blocking medication. The good news: 10-year breast cancer survival rates hover around 98 to 99 percent regardless of which surgical approach is chosen. Because DCIS cells are still confined inside a milk duct and haven’t spread into surrounding breast tissue, the goal of treatment is preventing them from ever becoming invasive cancer.
What DCIS Actually Is
DCIS stands for ductal carcinoma in situ. The cancer cells exist only inside a milk duct in the breast. They haven’t developed the ability to break through the duct wall and invade nearby tissue, which is why DCIS is classified as stage 0, sometimes called noninvasive or preinvasive breast cancer. Left untreated, some DCIS will progress to invasive breast cancer over time, though not all cases do. The challenge is that doctors can’t reliably predict which cases will progress and which won’t, so most women receive some form of treatment.
Surgery: Lumpectomy or Mastectomy
The two main surgical options are lumpectomy (removing the DCIS along with a margin of healthy tissue) and mastectomy (removing the entire breast). Most women with DCIS are candidates for lumpectomy, which preserves the breast. Surgeons aim for a margin of at least 2 millimeters of clear tissue around the DCIS, since studies show this reduces the chance of it coming back in the same breast.
Mastectomy is generally recommended when DCIS is widespread across a large area of the breast, when there are multiple separate areas of DCIS, or when clear margins can’t be achieved with lumpectomy. After mastectomy, local recurrence rates are very low, around 3.4 percent in one Cleveland Clinic study. Some women choose mastectomy for peace of mind even when lumpectomy is an option.
One detail worth knowing: if you’re having a mastectomy for DCIS, your surgeon will likely recommend a sentinel lymph node biopsy at the same time. This checks whether any cancer cells have reached the nearest lymph nodes. It’s not routinely done with lumpectomy for DCIS, but it is standard with mastectomy because once the breast is removed, the opportunity to go back and check those nodes is lost. A sentinel lymph node biopsy is also recommended if there’s any suspicion of microinvasion (tiny areas where cells may have started to break through the duct wall).
Radiation After Lumpectomy
When DCIS is treated with lumpectomy alone, there’s a meaningful risk of recurrence in the same breast. Adding radiation therapy after lumpectomy cuts that risk by more than half. This is why lumpectomy plus radiation is the most common treatment combination for DCIS.
Radiation is typically delivered to the affected breast over several weeks, though shorter courses (called hypofractionated radiation) are increasingly used. If you have a mastectomy, radiation is almost never needed because the entire breast tissue has been removed.
The 10-year breast cancer survival numbers are strikingly similar across approaches: 98.9 percent for lumpectomy plus radiation, 98.5 percent for mastectomy, and 98.4 percent for lumpectomy alone. What differs is the chance of a local recurrence, not the chance of dying from breast cancer. That distinction matters when you’re weighing your options. A recurrence after lumpectomy usually means more surgery, but it doesn’t significantly change your long-term survival.
Genomic Testing to Guide Radiation Decisions
Not every woman with DCIS benefits equally from radiation, and a genomic test can help sort that out. The Oncotype DX Breast DCIS Score analyzes a sample of the removed tissue and, combined with your age and the size of the DCIS, estimates your personal 10-year risk of local recurrence. When that estimated risk falls below 10 percent, skipping radiation may be reasonable.
This test changes treatment plans more often than you might expect. In one study, oncologists changed their radiation recommendations 28 percent of the time after reviewing the Oncotype result. Most of those changes (21 percent of all cases) were switches from recommending radiation to recommending against it. For women who want to avoid the time and side effects of radiation when it may not be necessary, this test provides useful clarity.
Hormone Therapy for ER-Positive DCIS
About 70 to 80 percent of DCIS is estrogen receptor-positive, meaning the abnormal cells are fueled by estrogen. For these women, taking tamoxifen after lumpectomy and radiation lowers the risk of both DCIS recurrence and new invasive breast cancer. This protection extends to both the treated breast and the opposite breast. A large meta-analysis found tamoxifen reduced the risk of invasive cancer in the opposite breast by about 43 percent compared to no tamoxifen.
If your DCIS tests negative for hormone receptors, tamoxifen doesn’t provide a measurable benefit. Hormone receptor testing is done on the tissue removed during surgery, so you’ll know your status before this decision needs to be made. Tamoxifen is typically taken daily for five years. For postmenopausal women, aromatase inhibitors are sometimes used as an alternative.
Active Surveillance Without Surgery
A newer approach being studied is active surveillance: monitoring low-risk DCIS with annual mammograms instead of operating right away. If imaging shows signs of progression, you would then undergo a biopsy and, if confirmed, surgery. Four major clinical trials (LORIS in the UK, LORD in Europe, COMET in the US, and LORETTA in Japan) are currently testing whether this strategy is safe for women with low-risk DCIS.
Some of these trials combine surveillance with hormone therapy, while others test surveillance alone. This approach is not yet standard care. It’s available only through enrollment in a clinical trial, and it’s limited to women whose DCIS is considered low grade and low risk. The results of these trials will eventually clarify whether some women can safely avoid surgery altogether, but for now, surgery remains the default recommendation.
Choosing Between Treatment Options
The decision between lumpectomy and mastectomy, and whether to add radiation or hormone therapy, depends on several factors: the size and grade of the DCIS, how much of the breast is involved, your hormone receptor status, your genomic test results, and your personal preferences about future monitoring and risk tolerance.
Women who choose lumpectomy with radiation will need regular follow-up mammograms, typically every six to twelve months for the first few years and then annually. Women who choose mastectomy have a lower chance of local recurrence and may have a simpler surveillance schedule, but face a bigger surgery and longer recovery. If breast reconstruction is important to you, that’s available after mastectomy and can often be started during the same operation.
Because long-term survival is excellent regardless of which path you choose, the treatment decision for DCIS is less about survival and more about balancing the intensity of treatment against the risk of recurrence and the impact on your quality of life.